Ehud Shoshani

Keine laufenden Positionen mehr

Health Technology

Consumer Services

Profil

Ehud Shoshani served as the Chief Executive Officer at Quintiles UK Ltd. and as the Medical Director at OMRIX Biopharmaceuticals, Inc. and Gamida Cell Ltd. He also worked as the Vice President-Clinical Affairs at Aevi Genomic Medicine, Inc. Shoshani holds a doctorate degree from Technion-Israel Institute of Technology, which he received in 1978.

Ehemalige bekannte Positionen von Ehud Shoshani

Unternehmen	Position	Ende
GAMIDA CELL LTD.	Technik-/Wissenschafts-/F&E-Leiter	-
Quintiles UK Ltd.	Präsident	-
Omrix Biopharmaceuticals, Inc. Omrix Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops biosurgical and immunotherapy solutions	Technik-/Wissenschafts-/F&E-Leiter	-
AEVI GENOMIC MEDICINE, INC.	Technik-/Wissenschafts-/F&E-Leiter	-

Sehen Sie sich die Erfahrung von Ehud Shoshani im Detail an

Ausbildung von Ehud Shoshani

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Ehud Shoshani im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	5
Omrix Biopharmaceuticals, Inc. Omrix Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops biosurgical and immunotherapy solutions	Health Technology
Technion-Israel Institute of Technology Technion-Israel Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Aevi Genomic Medicine, Inc. Aevi Genomic Medicine, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of treatments for auto-immune pediatric disease	Health Technology
Quintiles UK Ltd.
Gamida Cell Ltd. Gamida Cell Ltd. Pharmaceuticals: MajorHealth Technology Engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases	Health Technology